Session Type
Meeting
Search Results for Opioid
Oral Presentations
Abstract Number: Oral
SHM Converge 2021
Background: Despite evidence that the use of medications for patients with opioid use disorder (OUD) leads to reduced mortality and improved engagement in outpatient addiction treatment, these life-saving medications are underutilized in the hospital setting. This study reports the outcomes of a hospitalist-led interprofessional and multidisciplinary inpatient program, known as the B-Team (buprenorphine team), to […]
Abstract Number: 59
SHM Converge 2021
Background: Methylnaltrexone (MNTX) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC), which can be a serious consequence of opioid analgesia. We evaluated whether baseline osmotic agent (eg, milk of magnesia, polyethylene glycol, lactulose, sorbitol) or stimulant (eg, senna, bisacodyl) use affects the efficacy and safety of MNTX among a subgroup of […]
Abstract Number: 98
SHM Converge 2021
Background: Prior case reports and case-series reports have shown an association between Opioid use disorder and Thrombotic Thrombocytopenic Purpura (TTP). However, clinical data regarding Thrombotic Thrombocytopenic Purpura co-existing with Opioid use disorder are still lacking in the literature. We aim to study patient characteristics, epidemiology, co-morbidities, and clinical outcomes in these patients. Methods: We analyzed […]
Abstract Number: 169
SHM Converge 2021
Background: Naloxone is a medication that reverses opioid overdose in emergency situations and prevents deaths. A group of 55 Eastern Virginia Medical School (EVMS) medical students were trained by REVIVE!, a program that educates on how to recognize and respond to an opioid overdose emergency with the administration of naloxone. We evaluated whether there is […]
Abstract Number: 194
SHM Converge 2021
Background: Patients with Substance Use Disorder (SUD) are a nationwide concern. They have significant morbidity, mortality & for several reasons, such as comorbid psychiatric conditions, medication noncompliance, low income or poor access to healthcare services, have an increased risk of hospital readmissions. Processes aimed at reducing readmission rates in this population are important for improving […]
Abstract Number: 207
SHM Converge 2021
Background: Hospitalizations among patients with opioid use disorder (OUD) have skyrocketed in the past 10 years (1). These patients represent an ever-growing portion of the typical hospital medicine census and often have readmission rates greater than expected for their age and other health status. Discharge against medical advice (AMA) is common in this population, and […]
Abstract Number: 209
SHM Converge 2021
Background: Readmission among Inflammatory Bowel Disease (IBD) inpatients is common, as is opioid use. Opioid use for IBD has been associated with an increased risk of infection and death, but inconsistently with readmissions. Increasingly, cannabis is viewed as a potentially safer alternative to opioids, though with limited study of potential adverse outcomes such as hospital […]
Abstract Number: 224
SHM Converge 2021
Background: Biases related to people with substance use disorder (SUD) actually increase during time spent in formal medical education, and continue into practice. Leading health professional education groups across medicine, nursing, pharmacy, and social work, including the Association of American Medical Colleges (AAMC), have recognized addressing substance use disorders including stigma and bias as a […]
Abstract Number: 242
SHM Converge 2021
Background: Opioid overdose in the United States continues to rise. Naloxone is an opioid antagonist that is FDA-approved for reversing opioid overdose. Current CDC guidelines recommend prescribing naloxone to patients at high risk of opioid overdose, including patients with concurrent benzodiazepine use, a prior history of overdose, and those receiving high doses of opioids (>50 […]
Abstract Number: 293
SHM Converge 2021
Background: Opioid use disorder (OUD) is a chronic relapsing disease that has become an epidemic in the United States. Overdoses of prescription and illicit opioids have killed almost 450,000 Americans between 1999-2018 (1). Guidelines on OUD management recommend, in combination with behavioral therapy, opioid agonist therapy as the first-line treatment option with antagonist therapy as an alternative option. OUD-related inpatient admissions represent […]